SCHEMBL3097101

SCHEMBL3097101

COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@]2(OC)c2ccc(F)c(F)c2)C2CC2)c(Cl)cn1

nearest known ligand 0.65

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
REN P00797 20/20 0.65
KCNH2 Q12809 13/20 0.65
CYP3A4 P08684 3/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3112098 0.91 REN (0.78) RENKCNH2CYP3A4
SCHEMBL3112119 0.91 REN (0.78) RENKCNH2CYP3A4
SCHEMBL3091991 0.88 REN (0.83) RENKCNH2CYP3A4
SCHEMBL3091977 0.88 REN (0.83) RENKCNH2CYP3A4
SCHEMBL3103469 0.86 REN (0.52) RENKCNH2CYP3A4
SCHEMBL3100333 0.86 REN (0.83) RENKCNH2CYP3A4
SCHEMBL3100320 0.86 REN (0.83) RENKCNH2CYP3A4
SCHEMBL3418495 0.82 REN (0.75) RENKCNH2CYP3A4
SCHEMBL3107716 0.81 REN (0.84) RENKCNH2CYP3A4
SCHEMBL3108235 0.81 REN (0.84) RENKCNH2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100249163-A1 RENIN INHIBITORS MERCK CANADA INC. (CA) 2010-09-30 US claimed
EP-2229363-A1 RENIN INHIBITORS Merck Frosst Canada Ltd. (CA) 2010-09-22 EP claimed
WO-2009070869-A1 RENIN INHIBITORS MERCK FROSST CANADA LTD. (CA) 2009-06-11 WO claimed
US-20100249163-A1 RENIN INHIBITORS MERCK CANADA INC. (CA) 2010-09-30 US disclosed
EP-2229363-A1 RENIN INHIBITORS Merck Frosst Canada Ltd. (CA) 2010-09-22 EP disclosed
WO-2009070869-A1 RENIN INHIBITORS MERCK FROSST CANADA LTD. (CA) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249163-A1 RENIN INHIBITORS REN, ACE, AGTR1 REN 1/4885KCNH2 1176/4885CYP3A4 1183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.